MYOMO, INC. - 8-K Filing
Myomo reported Q1 2026 revenue of $10.1 million, up 3% year-over-year, with 49% of revenue from recurring patient sources, up from 25% in Q1 2025. The company received 239 MyoPro orders, up 12% year-over-year, and narrowed its net loss to $3.0 million, or $0.07 per share, compared to $3.5 million, or $0.08 per share, in Q1 2025. Gross margin expanded to 68.2%, up 100 basis points year-over-year, and the company expects Q2 revenue between $10.3 million and $10.8 million. (Items: 2.02 Results of Operations and Financial Condition)
Tickers: $MYO